RepliCel Forms Clinical Advisory Board to Support the Development of RCT-01 for the Treatment of Chronic Tendinosis

RepliCel Forms Clinical Advisory Board to Support the Development of RCT-01 for 
the Treatment of Chronic Tendinosis 
VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 10/30/13 -- RepliCel
Life Sciences Inc. (OTCBB:REPCF)(CNSX:RP), a clinical stage
biopharmaceutical company focused on the development of autologous
cell therapies for regenerative medicine, today announced the
formation of a clinical advisory board (CAB) to support the clinical
development of its RCT-01 autologous cell therapy for the treatment
of a variety of chronic tendon injuries including Achilles, patellar
and elbow tendinosis. The board, chaired by Ross G. Davidson, MBChB,
will provide its expertise and guidance on all aspects of the
clinical trial program. Additional members include David A. Connell,
MBBS, and Dr. Jack E. Taunton, M.D. 
"RepliCel's RCT-01 addresses a serious and chronic disease of the
tendon caused by a cycle of injury, healing and re-injury which
results in frequent periods of pain and limited function," stated
David Hall, CEO of RepliCel. "Efficacy and safety results from
initial studies led by Dr. Connell form the basis for our current
plan to conduct a large efficacy trial beginning with Achilles
tendinosis. We are delighted to have these key opinion leaders join
with RepliCel to guide the development of our promising treatment for
chronic tendinosis." 
"Regenerative cell therapy using RepliCel's approach addresses the
inherent cellular deficit of active fibroblasts seen in chronic
tendinosis and represents a significant step forward," said Ross G.
Davidson, MBChB, Clinical Advisory Board Chairman. "RCT-01's
autologous hair follicle-derived fibroblast cells express
significantly more Type I collagen than adipose derived fibroblasts,
which should make this an ideal candidate to restore function for
those patients suffering from chronic tendinosis." 
"My original clinical work on Achilles, patellar and elbow
tendinopathies demonstrated the clinical promise of addressing the
cellular deficit of active fibroblasts in chronic tendinosis, the
cells necessary to complete the healing cycle," stated David A.
Connell, MBBS. "RepliCel has isolated a source of fibroblasts which
produce higher levels of Type I collagen than the adipose derived
fibroblasts which I used in my human proof of concept trials. RCT-01
has the potential to become the standard of care in chronic
tendinosis." 
"Chronic tendinosis is not only an increasing problem in sports
medicine, but also in everyday life as our aging populations get more
active," stated Jack E. Taunton, M.D. "The successful direct
stimulation of resident fibroblasts has eluded clinicians, but
RepliCel's approach addresses this issue by injecting a patient's own
fibroblasts directly into the damaged tendon. This approach holds
tremendous promise as a therapy in tendonopathy." 
The background for each appointed member of the Clinical Advisory
Board is as follows: 
Ross G. Davidson, MBChB, Chairman 
Dr. Davidson has facilitated the recovery of numerous high profile
professional athletes during his 30 year career in sports medicine.
He is currently a member of the New Zealand Orthopaedic Association
and the Canadian Orthopaedic Association. He is the past president of
the National Hockey League Physicians Society, past head physician
and orthopaedic consultant for the Vancouver Canucks Hockey Club
(NHL), past orthopaedic consultant to the Vancouver Grizzlies
Basketball Team (NBA), and past orthopaedic consultant to the
Canadian Football League Players Association. Dr. Davidson held the
position of clinical professor, department of orthopaedics at the
University of British Columbia until 2000 and currently has
appointments to the Auckland Surgical Centre and Southern Cross
Hospital in New Zealand. He is also the Director of the Post-Graduate
Programme in Sports Medicine at the University of Auckland. Dr.
Davidson is a highly regarded and sought-after lecturer and is
published in 17 scientific publications on sports-related injuries
and treatments. 
Jack E. Taunton, M.D. 
Dr. Jack Taunton serves as Professor in the Faculty of Medicine,
Division of Sports Medicine at the University of British Columbia and
has a clinical practice in sports medicine at the Allan McGavin
Sports Medicine Centre where he was the director for over 25 years
after co-founding the centre in 1979. Thirty years ago, he co-founded
Sportmed BC while president of the Sports Medicine Council of Canada.
Dr. Taunton is also currently the director of Sports Medicine for
Fortius Sport and Health and is on the board of directors of the
Canadian Centre for Ethics in Sport. He served as the Chief Medical
Officer (CMO) for the Vancouver 2010 Olympic and Paralympic Winter
Games and CMO for Canada at the Sydney Olympics, two Pan American and
two World Student Games. He was the Women's Team Physician and
Association Coordinating Physician for Field Hockey Canada for over
25 years. Dr. Taunton was the Team Physician for the Vancouver
Grizzlies NBA team during its time in Vancouver. He was co-founder of
the Vancouver Marathon, the Vancouver Sun Run and most recently the
UBC Grand Prix of Cycling. He was inducted into the BC Athletics
Sports Hall of Fame and the Burnaby Sports Hall of Fame and was named
to the Globe and Mail 2012 Power 50. In 2012, he was the recipient of
the Queen's Diamond Jubilee Medal. 
David A. Connell, MBBS 
Dr. Connell is a recognized international authority on muscle and
tendon injuries. His private practice is dedicated to musculoskeletal
radiology and he serves as an associate professor in the Faculty of
Medicine at Monash University. In 2010, he established a diagnostic
and treatment facility for elite athletes in AAMI stadium, Olympic
Park in Melbourne. He has authored 91 publications and has spoken at
major meetings in 19 different countries. Dr. Connell is the
past-president of the Australasian Musculoskeletal Imaging Group,
serves on the editorial board of five journals, is an instructor on
the Erasmus MRI European diploma, and is an elected fellow to the
Faculty of Sports & Exercise Medicine (UK). 
About RepliCel Life Sciences 
RepliCel is a clinical stage biopharmaceutical company focused on
developing autologous cell therapies. RepliCel Hair-01 (RCH-01) is a
cellular treatment for androgenetic alopecia (pattern baldness).
Shiseido Company, Limited has an exclusive geographic license for
RCH-01 in certain Asian countries including Japan, China and South
Korea. RepliCel Tendon-01 (RCT-01) is a cell therapy for the
treatment of chronic tendon injuries. Both product candidates are
based on RepliCel's innovative technology which utilizes cells
isolated from a patient's own healthy hair follicles to address
specific cellular deficits. For additional information please visit
www.replicel.com.  
Notice Regarding Forward Looking Statements 
This press release contains projections and forward-looking
statements, as that term is defined under applicable securities laws.
Statements in this press release, which are not purely historical,
are forward-looking statements that relate to the approval and
commercialization of the Company's hair restoration process, and the
Company's development of its Achilles tendon technology. These
statements are only predictions and involve known and unknown risks
which may cause actual results and the Company's plans and objectives
to differ materially from those expressed in the forward-looking
information, including: negative results from the Company's clinical
trials; the effects of government regulation on the Company's
business; risks associated with the Company's ability to obtain and
protect rights to its intellectual property; risks and uncertainties
associated with the Company's ability to raise additional capital;
and other factors beyond the Company's control. Although the Company
believes that the expectations reflected in the forward-looking
statements are reasonable, it cannot guarantee future results, levels
of activity or performance. Further, any forward-looking statement
speaks only as of the date on which such statement is made, and,
except as required by applicable law, the Company undertakes no
obligation to update any forward-looking statement to reflect events
or circumstances after the date on which such statement is made or to
reflect the occurrence of unanticipated events. New factors emerge
from time to time, and it is not possible for management to predict
all of such factors and to assess in advance the impact of such
factors on the Company's business or the extent to which any factor,
or combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statement.
Readers should consult all of the information set forth herein and
should also refer to the risk factor disclosure outlined in the
Company's annual report on Form 20-F for the fiscal year ended
December 31, 2012 and other periodic reports filed from time-to-time
with the Securities and Exchange Commission on Edgar at www.sec.gov
and with the British Columbia Securities Commission on Sedar at
www.sedar.com. 
Contacts:
CORPORATE CONTACT:
RepliCel Life Sciences Inc.
Tammey George
Director of Communications
604-248-8696
tg@replicel.com 
INVESTOR CONTACTS:
Westwicke Partners, LLC
Stefan Loren, Ph.D.
Managing Director
(443) 213-0507
sloren@westwicke.com 
Westwicke Partners, LLC
Robert H. Uhl
Managing Director
(858) 356-5932
robert.uhl@westwicke.com
 
 
Press spacebar to pause and continue. Press esc to stop.